TY - JOUR T1 - Outcomes for COPD pharmacological trials: from lung function to biomarkers JF - European Respiratory Journal JO - Eur Respir J SP - 416 LP - 469 DO - 10.1183/09031936.00099306 VL - 31 IS - 2 AU - M. Cazzola AU - W. MacNee AU - F. J. Martinez AU - K. F. Rabe AU - L. G. Franciosi AU - P. J. Barnes AU - V. Brusasco AU - P. S. Burge AU - P. M. A. Calverley AU - B. R. Celli AU - P. W. Jones AU - D. A. Mahler AU - B. Make AU - M. Miravitlles AU - C. P. Page AU - P. Palange AU - D. Parr AU - M. Pistolesi AU - S. I. Rennard AU - M. P. Rutten-van Mölken AU - R. Stockley AU - S. D. Sullivan AU - J. A. Wedzicha AU - E. F. Wouters A2 - , Y1 - 2008/02/01 UR - http://erj.ersjournals.com/content/31/2/416.abstract N2 - The American Thoracic Society/European Respiratory Society jointly created a Task Force on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations. ER -